share_log
Reuters ·  Apr 25 07:00
Regeneron Pharmaceuticals Inc - Mammoth Is Eligible to Receive up to $370 Mln per Target in Development, Regulatory and Commercial Milestone Payments
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment